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CASE PRESENTATIONS
Patient 1. An 18-month-old girl presented with paleness and oliguria
preceded by non-bloody diarrhea that had started five days previously. On
admission, her blood pressure was 120/85 mm Hg (90th percentile, 105/68
mm Hg) and she was anuric. Her blood urea concentration was 168 mg/dl
and hematocrit 22%; a blood smear contained numerous fragmented
erythrocytes. Her serum electrolytes were: sodium, 132 mEq/liter; potas-
sium, 5.8 mEq/liter; chloride, 102 mEq/liter; and bicarbonate, 15.2 mEqI
liter. A diagnosis of the acute hemolytic-uremic syndrome (HUS) was
made. She received one packed red blood cell transfusion. After three
days of anuria and with her blood urea level reaching 285 mgldl, peritoneal
dialysis was started. Her anuria persisted for five days and she was
discharged after two weeks, normotensive with a blood urea of 68 mg/dl
and a serum creatinine of 0.85 mgldl. On followup she remained normo-
tensive; her urea was 19 mg/dl one month after the beginning of the acute
disease. Her serum creatinine concentration was normal (0.6 mg/dl) at one
year followup, but she still had proteinuria of 100 mg/dl in the first
morning sample. Subsequent measurements revealed decreased protein-
uria, which became intermittent after four years and has remained absent
since the eighth year of followup. Her last evaluation, 13 years after the
acute illness, revealed a normal adolescent girl, with normal growth and
development; a blood pressure of 110/65 mm Hg; serum creatinine
concentration, 0.8 mg/dl; and a normal urinalysis.
Patient 2. A 7-month-old boy was admitted to the hospital because of
generalized convulsions. Diarrhea and pallor had been present for three
days. He had been anuric for the previous 11 hours. Despite administra-
tion of intravenous phenobarbital, the baby continued to have intermittent
hypertonia, alternating with hypotonia. He appeared normohydrated, and
his blood pressure was 160/80 mm Hg (90th percentile, 105/67 mm Hg).
His blood chemistries showed: hematocrit, 26%; urea, 140 mg/dl; sodium,
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140 mEq/liter; potassium, 5.2 mEq/liter; chloride, 108 mEq/liter; bicar-
bonate, 13.6 mEq/liter; and platelet count, less than 50,000/mm3. The
peripheral blood smear showed many fragmented erythrocytes. Acute
HUS was diagnosed. Reserpine was given intramuscularly, and peritoneal
dialysis was initiated on the second day, when his blood urea was 210
mg/dl.
Anuria persisted for eight days, during which he was dialyzed five times.
He was discharged after three weeks with a blood urea of 105 mg/dl. A
low-protein diet and salt restriction were prescribed, as was alphamethyl-
dopa for his hypertension. One month after admission, his blood pressure
was under control; his urea was 82 mg/dl, and his serum creatinine, 1.4
mgldl. He was followed at our hospital for six months and returned to his
home province with controlled blood pressure; urea, 41 mg/dl; and serum
creatinine, 1.1 mg/dl. He returned for a checkup at 5 years, 11 months of
age, about five years after the acute illness. He was normotensive without
medication; the urea was 36 mg/dl and the serum creatinine, 0.8 mg/dl. His
urine contained minimal protein. Followup measurements at his home
showed persistent subnephrotic proteinuria but normal serum creatinine
levels until 12 years after the acute HUS, when his serum creatinine rose
to 1.2 mg/dl. The serum creatinine level slowly increased thereafter (Fig.
1). He became hypertensive 14 years after the acute HUS and returned at
16 years of age in end-stage renal failure, entering our program of
hemodialysis and transplantation.
Patient 3. A 17-month-old girl was admitted to the hospital because of
diarrhea over five days with bloody striae over the last two days. She was
pale and irritable. Her blood pressure was 127/82 mm Hg (90th percentile,
105/69 mm Hg). She had been anuric for two weeks.
Her blood chemistries on admission were: hematocrit, 18%; urea, 95
mg/dl; serum creatinine, 3.6 mg/dl; sodium, 132 mEq/liter; potassium, 5.8
mEq/liter; chloride, 104 mEq/liter; bicarbonate, 15 mEqlliter; and platelet
count, 86,000/mm3. The peripheral blood smear showed anisocytosis,
poikilocytosis, and fragmented red cells. The diagnosis of acute HUS was
made. The patient was given a packed erythrocyte transfusion, an antihy-
pertensive medication, and she was dialyzed via the peritoneal route. She
began to urinate two weeks later, although she remained oliguric for
another week.
The child was followed as an outpatient, and she required propranolol
to keep her blood pressure under control. She had persistent proteinuria,
and her blood urea concentration remained between 80 mg/dl and 100
mgldl even with protein restriction. Her serum creatinine level remained
elevated and increased slowly until 2 years and 9 months after the acute
episode (Fig. 2).
When she was 4 years, 4 months old, she received her mother's kidney.
Immunosuppressive medication consisted of prednisone and azathioprine;
she had no acute rejection. One month post transplantation, her blood
pressure was 120/75 mm Hg while she was receiving propranolol, her
serum creatinine was 0.4 mgldl, and her blood urea was 19 mg/dl. Five
months after transplantation, her antihypertensive medication was with-
drawn. She remained in good health, growing adequately and leading a
normal life. At last followup, 12 years and 10 months after transplantation,
this 17-year-old girl's height is 151 cm and her blood pressure is 120/75 mm
Hg without antihypertensive medication. Her serum creatinine level is
0.92 mg/dl, with an estimated creatinine clearance of 90 ml/min/1.73 m2.
DISCUSSION
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Fig. 1. Patient Two. Evolution of serum creatinine.
Table 1. Pathogenesis of HUS
Associoted with infection
Bacterial cytotoxin (E. coli, Shigella, Salmonella)
Pneumococcal neuraminidasc
Viral
idiopathic or "atypical"
Sporadic
Recurrent
Hereditary
Associated with systemic conditions
Cancer
Pregnancy
Malignant hypertension
Transplant rejection
Glomerulonephritis
Exposure to toxins
Cyclosporine
Mitomycin
Radiation
0 1 2 3
Medical School, Buenos Aires, Argentina): The hemolytic-uremic
syndrome was first described by Gasser et al more than 40 years
ago [I]. Since then, several studies have established the multisys-
temic character of the thrombotic microangiopathy that consti-
tutes the basic anatomic lesion of HUS [2—4]. In 1978, Kaplan and
Drummond emphasized the different clinical entities that can
present as this syndrome [5]: idiopathic sporadic or epidemic
forms, syndromes occurring post pregnancy or oral contraceptive
use, a lesion associated with infection, a familial or hereditary
syndrome, and post-renal-transplantation HUS. With our current
knowledge, I believe that these entities can be classified as (1)
HUS associated with infections, including the "classic" epidemic
(enteropathic) form with its high prevalence in children; (2)
idiopathic HUS, which can be hereditary or sporadic, and prob-
ably is related to primary endothelial dysfunction; (3) HUS
associated with systemic diseases or other precipitating factors;
(4) and HUS resulting from exposure to toxins (drugs or radia-
tion) (Table 1).
In children, the epidemic form can be difficult to differentiate
from the "atypical" or idiopathic form. An intrinsic defect in the
different endothelial functions that protect the microvasculature
from thrombosis is the generally accepted hypothesis for the latter
[6]. The definition generally used for its diagnosis requires the
absence of gastrointestinal symptoms in the prodromic phase [7].
As we will see when I speak of epidemiology, a small group of
children with evidence of verotoxin-producing E. coli (VTEC)
infection does not have diarrhea at presentation and may be
erroneously classified as "atypical." One subgroup encompasses
children who suffer one or more recurrences [8]. These children
have a higher incidence of affected siblings, a high mortality rate,
and a high chance of recurrence in the transplanted kidney [9]. In
some of these patients, hypocomplementemia characterized the
recurrence [10, 11]. Finally, an extensive analysis of the familial
forms can be found in a chapter by Kaplan [12]. Some of these
children have the HUS associated with verotoxin due to home
contact. Others have hereditary forms; in these cases disease
recurrence, hypocomplementemia, or recurrence in the renal
graft is common, and they are included within the idiopathic HUS.
For the purposes of this Forum, I will limit our discussion to the
classic epidemic form.
When I was a resident in pediatrics in Argentina at the
beginning of the 1960s, we interpreted the clinical picture in these
infants as due to sepsis of gastrointestinal origin. We believed the
anemia and thrombocytopenia to be part of the disseminated
intravascular coagulation and the renal insufficiency to be due to
acute tubular necrosis. The syndrome had been described in 1955
in a Swiss journal [1], but not until 1962 was the Argentine
experience with HUS presented in a paper on acute renal failure
(ARF) [13]. Gianantonio, to whom we are paying homage in this
Forum, and his coworkers from the Children's Hospital of Buenos
Aires, published the first complete description of the clinical
features and evolution of the syndrome in more than 50 children
with HUS two years later [14]. As knowledge accumulated about
the different nosologic entities presenting as HUS and the
epidemiologic characteristics of the syndrome, we became aware
that in our country, diarrhea accompanied the other symptoms in
at least 90% of affected children. In 1981, we reviewed 95 children
with HUS; gastrointestinal symptoms in the prodromic phase
were present in 93% (unpublished data). We can speculate
retrospectively that these patients' disease probably was related to
cytotoxins of enterobacteriae [15], Thirty years later, we still have
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Fig. 2. Patient Three. Evolution of serum creatinine.
Bloody
U
11110
76° b
71°c
51%
______25%
1710 Nephrology Fonm: HUS in children
Diarrhea
Vomiting
Fever
Edema
Arterial
hypertension
Anuria
Upper resp.
illness
Fig. 3. Prevalence of prodromal signs and symptoms.
no useful treatment, other than supportive measures, in this
"classic" form of the syndrome [16—21].
Epidemiology
Major neurologic
signs
Purpura
Seizures
Let me begin by presenting an overview of the natural history of
enteropathic, or diarrhea-associated, HUS. In the areas where
HUS in children is endemic, the strong association with diarrhea
prompted a search for an infectious agent in the stool. The
sophisticated analysis by Chesney and Kaplan [22] on the patient
discussed by Ullis and Rosenblatt [23] as having disseminated
intravascular coagulation, and the epidemics of shigellosis com-
plicated by HUS in Bangladesh [24] disclosed a close link between
enterobacteriae and HUS. In 1983, Karmali et at demonstrated a
causal association between VTEC and HUS [25]. This finding was
unequivocally confirmed two years later [26]. Between 1986 and
1989, three reports from Argentina suggested that the verotoxin-
producing bacterium E. coli was the major cause of classic,
epidemic HUS in this geographic area [27—29]. Lopez et al also
showed that the E. coli serotype prevalent in other parts of the
world, namely 0157:H7, was present in fewer than 5% of Argen-
tine children with HUS, but that 48% of them had evidence of
free fecal toxin; this finding strongly suggested the presence of
different strains of the bacterium in Argentina [29]. On the other
hand, the frequency of cytotoxin-associated gastroenteritis in
Argentina is approximately 23%, much higher than the 0.6% to
2.4% in other parts of the world [30].
Clinical picture
The clinical picture of the acute phase of HUS in the three
patients discussed today is typical of the epidemic form of the
disease. For a few days preceding the sudden Onset of pallor and
central nervous system involvement, they all had diarrhea. initial
laboratory data showed a decreased hematocrit with fragmented
erythrocytes in the peripheral blood smear and a low platelet
count, characteristic of microangiopathic hemolytic anemia. The
blood urea level was elevated, and all three patients were anuric
on admission. The rest of the laboratory studies reflected alter-
ations due to ARF. Diarrhea and vomiting are the most frequent
of the prodromal signs and symptoms that occur in HUS. Figure
3 presents the prevalence of these prodromal signs and symptoms
in 274 children admitted to two hospitals in Argentina whom we
studied [31]. The acute stage of the disease was marked by
hypertension, edema, hematologic abnormalities, and anuria;
Figure 4 illustrates the prevalence of these and other findings in
the acute stage [31]. The most frequent cause of ARF in Argen-
tine children, HUS was diagnosed in 65% of 237 children
admitted for ARF to our service. Another distinct feature of the
acute form of HUS is the high incidence of neurologic involve-
ment. Central nervous system (CNS) sequelae [3, 32—40] are
infrequent. Hematologic changes occur only during the acute
phase. The literature contains only occasional reports of persis-
tent lesions in the liver [41], pancreas [42—45], colon [46], or other
organs [38].
Fortunately, more than 95% of patients recover from the acute
phase of the illness [31, 32]. The mortality rate is less than 5%
(range, 0.5% to 4.5% between 1978 and 1993 in Argentina; data
from the registry of the Nephrology Committee of the Argentine
Society of Pediatrics).
The three patients presented today illustrate different courses
of the renal lesion of the HUS. The first patient seems to have
been cured after 13 years of followup. The second patient
experienced a moderately severe acute stage and recovered from
the ARF; his creatinine clearance (Ccr) eventually returned to
normal. But he had persistent proteinuria and many years later
developed hypertension, which then progressed to end-stage renal
failure (ESRF). The third child had a very severe acute phase and
arrived at ESRF without ever recovering acceptable renal func-
tion. She received a successful renal transplant.
After recovery from the ARF of HUS, renal function follows
one of two patterns. In a few patients, the serum creatinine
concentration does not totally return to the normal range, and
ESRF develops relatively rapidly, an average of 4 years after the
acute illness [47], as in Patient 3. We observed this course in 6 of
14 children who received renal transplants for HUS. In the
second, more common pattern, the vast majority of patients
recover normal renal function, at least as measured by Ccr or
serum creatinine concentration. One year after the acute episode,
one-half of them have a normal serum creatinine concentration
and no proteinuria (by spot sample testing). In 6%, the Ccr is
normal but proteinuria (rarely in the ncphrotic range) is present.
The remaining 45% have a reduced Ccr with proteinuria. Patients
in the last two groups also can he hypertensive (Fig. 5). In our own
study of patients after three years of followup, the proportion of
patients with normal Ccr and no proteinuria increased to 62%; the
group with normal Ccr but with proteinuria increased to 14%; and
those with a diminished Ccr fell to 24%. Thus, some patients
continue to recover from the acute insult even after the first year
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124 40 19 41 5—13 3
128 62 14 24 3 31
118 63 18 19 10—19 48
of followup [31]. Spizzirri et a! reviewed patients from the same
cohort followed for more than 10 years and found that 63% still
had normal Ccr and no proteinuria; 18% had normal Ccr with
persistent proteinuria; only 16% now had a reduced Ccr; and
3.4% were in ESRF (Fig. 5) [48]. One patient developed ESRF 20
years after the acute episode. We also have known of occasional
patients who began chronic dialysis as long as 22 years after their
acute illness: among our 14 patients with HUS who received renal
transplants, this slow course of progression was observed in 8
children, This group required a renal graft in an average of 9.8
years after onset of the acute disease [47]. Analysis of these
clinical data shows that children who are doing well after three
years of followup are highly likely to continue to do well for many
years thereafter; only few patients develop proteinuria after
having normal findings for many years.
Studies from around the world have shown a similar proportion
of patients with a classic HUS following the same course (Table 2)
[3, 31, 48, 50—54]. We believe that in comparing outcomes in
patients with HUS, one should select those with most patients
having the diarrheal form of the disease. The outcome generally is
worse in patients with the atypical forms of HUS [7, 55, 56].
Pathogenesis
Several years ago, we suggested that patients with HUS whose
renal function deteriorated after a period of normal function
—
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Fig. 6. Mean CIN before and 2 hrs after a protein load in HUS patients
at follow-up. Cross-hatched bar: HUS; horizontal-hatched bars: controls.
(measured by serum creatinine levels or Ccr) [57] did so because
of hyperifitration injury to the remaining nephrons [58, 59]. These
patients almost always had associated proteinuria and also often
had hypertension. Three lines of research have produced data
compatible with that hypothesis. In our study [57], 4 of 12 patients
with normal Ccr many years after the acute stage of their disease
were unable to increase their inulin clearance when challenged
with protein loads [60]. One possible interpretation of this finding
is that these children are utilizing their "functional reserve" (prior
to the protein load) in the presence of a reduced nephron mass
[60]. Bosch's recent review suggests that the best way to quantitate
this diminished mass is determination of the maximal filtration
capacity [61], namely, the maximum GFR achieved after a stan-
dardized protein load, and comparison of that determination with
normal values for age. The mean peak inulin clearance after the
protein load in the 12 HUS patients we studied was 84.9 ml!min/
1.73 m2, significantly lower than that in normal children (154.7
ml/min/1.73 m2) (P < 0.025) (Fig. 6) [57]. Not too surprisingly, the
relation between creatinine clearance and inulin clearance was
disproportionally high in some of the 12 children; tubular creati-
nine oversecretion probably maintained the normal serum creat-
mine levels.
The second line of research implicating hyperfiltration injury
comes from Perelstein et al, who showed that some children who
had completely normal clinical and laboratory findings years after
an acute episode could develop microalbuminuria [62]. The
authors speculated that increased filtration of albumin, implicated
as the predictor of progressive lesions in other renal diseases [63],
might cause the subsequent loss of renal function.
A third line of inquiry was reported by Habib and coworkers,
who, studying sequential pathologic specimens, established that
the proportion of glomeruli involved in the acute insult was the
same as the proportion of scarred glomeruli later [4]. Histologic
changes in biopsy specimens from patients with chronic 1-IUS [3,
64] show focal and segmental sclerosis and mesangial expansion in
the glomeruli. These observations also suggest a hemodynamic
mechanism as the cause of progressive scarring and progressive
loss of renal function.
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Fig. 5. Renal status at one, three, and >10 years of follow-up after the
acute HUS [31, 48]. Hatched bar: normal Ccr, no proteinuria; vertical-
striped bar: normal Ccr, proteinuria; open bar: decreased Ccr, proteinuria.
Table 2. Long-term course of renal involvement in HUS
a Normal: no hypertension, no proteinuria, and normal creatinine
clearance
b Prot: proteinuria; HBP: hypertension; Ccr: creatinine clearance
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Many studies have searched for findings in the acute stage of
HUS that would precisely predict the late course of the illness.
The presence of diarrhea and the characteristics of classic,
epidemic HUS are associated with a better prognosis; the vari-
ables pointing to a poor prognosis are those associated with the
initial destruction of a larger number of nephrons. Not too
surprisingly, the presence of anuria and its duration as well as the
need for, and duration of, dialysis are the variables commonly
reported to predict late outcome [48—54]. As 1 mentioned earlier,
studies of the pathologic features in the acute phase have shown
that the percentage of compromised glomeruli can predict the late
course [4, 50]. Persistent hypertension also increases the risk for
chronic sequelae [3, 31, 48—54]. Severe extrarenal manifestations
[65], such as marked CNS symptoms [51, 54] and bloody diarrhea
or rectal prolapse [66], also are associated with a poor long-term
outlook. These signs probably simply reflect a more severe
disseminated microangiopathic process. Recently, Renaud and
coworkers concluded that age at onset, long considered of prog-
nostic significance, is not. They demonstrated that the difference
in outcome between infants and older children is simply due to the
higher frequency of the atypical subset of HUS (with its known
poorer outcome) in older children [56].
Management of chronic renal disease following acute HUS
Children who have normal creatinine clearance but persistent
proteinuria one year after an acute episode of HUS are at risk of
developing progressive renal failure [31, 48]. Persistent hyperten-
sion also is a predictor of a poor outcome. However, even patients
with a normal Ccr, no proteinuria, and normal blood pressure can
develop progressive renal insufficiency. Our approach is to start
treatment if the patient has persistent proteinuria of any degree
one year after the acute episode. First, we limit the protein in the
diet to the recommended dietary allowance [67]'; most middle
class children in our country consume amounts exceeding it. Next,
we try to reduce blood pressure to average or low-normal values
with ACE inhibitors. Third, even if the patient has normal blood
pressure, we administer angiotensin-converting-enzyme (ACE)
blockers. Although there is no conclusive evidence that this
treatment program prevents the progression of HUS, studies in
experimental animals [68, 69] and in other human renal diseases
in which a similar mechanism might be present [70—72] have
demonstrated a reduction in proteinuria and a diminution in the
rate of functional deterioration. Briones and colleagues from the
Pediatric Hospital of Buenos Aires have reported in abstract that
administration of ACE inhibitors decreased proteinuria from
63.5 11.2 mg/m2/hr to 9.8 2.0 mg/m2/hr in 25 children with
renal sequelae post HUS [73]. A long-term, prospective multi-
center study of a larger number of patients will he needed to
provide definitive conclusions regarding the efficacy of a low-
protein diet or ACE inhibition in patients with renal sequelae
following HUS.
Hemolytic-uremic syndrome accounts for about 20% of chil-
dren who enter ESRF programs in Argentina [74]. Since the
report from Cerilli et a! in 1972 [75], renal transplantation has
One has to be cautious in reducing dietary protein, since you can cause
other essential components (calcium, zinc, iron) to fall below their
recommended dietary allowances [67].
become a routine treatment for children with HUS who progress
to ESRF. Although scattered case reports describe recurrence of
HUS in the graft [9, 76—82], several groups have found no
recurrence of HUS in a substantial number of patients [47,
83—87]. In addition, Gagnadoux and colleagues, although not
observing recurrences in the epidemic form, reported that pa-
tients who received renal grafts because of HUS had a worse
long-term prognosis than did children whose original renal dis-
ease was not HUS [86].
Three problems complicate an analysis of the risk of recurrence
of HUS in a transplanted kidney: (1) Thrombotic microangiogra-
phy can be the pathologic pattern of acute immunologic rejection
[79]. (2) Thrombotic microangiopathy has been seen in renal
allografts in patients receiving cyclosporine whose original disease
was not HUS [88—90] and in patients with bone marrow [91, 92]
or liver transplantation [93]. (3) Recurrence has been reported
predominantly in older children and in adults, and in patients who
had recurrent or non-epidemic familial types of HUS [9, 76—81].
When we first reviewed our own experience with transplantation
in children with HUS, we found that the only patient who had a
recurrence that led to the loss of his graft (two months post
transplantation) was an 8-year-old boy who had had a severe,
acute HUS not preceded by gastrointestinal symptoms. He did not
recover from the acute failure and required hemodialysis until
transplantation. His brother had had non-diarrheal HUS, equally
severe, 5 years previously [47]. Since then, we have transplanted
kidneys into 4 other children with atypical HUS, and we have not
observed another recurrence. More recently, we reviewed the
course of 23 renal transplants in 20 children whose original
disease had been HUS [94]. Hemolytic-uremic syndrome had
been preceded by diarrhea in 16 patients who had presented with
the classic epidemic type; this group received 19 grafts. The
survival of these 19 grafts, maintenance of stable renal function,
incidence of acute rejection, and prevalence of proteinuria and
hypertension were compared with the same measures in a ran-
domly selected group of 19 children who received renal trans-
plants because of ESRF not due to HUS ("controls"). Mean
followup in both groups was 5 years, with a range of ito 11 years.
Actuarial survival of the grafts (in patients with or without
preceding HUS) and of the grafts with normal serum creatinine
was similar in the two groups (P = 0.73 and 0.27, respectively,
log-rank test) (Figs. 7, 8). Mean survival of the grafts was 7.16
years in the HUS patients versus 8.53 years in the controls (P, NS).
Mean survival with a normal serum creatinine was 2.07 (HUS)
versus 2.71 years (controls) (P, NS). There were 14 acute rejec-
tions in the HUS patients versus 8 episodes in the control group
(P, NS). Prevalence of proteinuria and hypertension at 1 and 5
years post transplantation was similar for the two groups. No
evidence of thrombotic microangiopathy was seen in the 6 trans-
planted kidneys surigically removed or in the 6 biopsies per-
formed for other diagnostic purposes. We conclude that patients
who receive renal transplants for classic epidemic HUS have a
very low risk of disease recurrence and that the long-term
outcome of the grafts in these patients is not different from that
in patients with ESRF from other causes. Moreover, in patients
whose original disease was classic HUS, the use of cyclosporine A
in 12 of the 19 grafts did not seem to increase the risk of
recurrence.
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Conclusion QUESTIONS AND ANSWERS
In the classic, epidemic form of FIUS in children, mortality in
the acute stage now is lower than 5%. Children usually die due to
intercurrent infection or severe neurologic, intestinal, or myocar-
dial complications associated with the more severe patterns of the
acute disease. Treatment in the acute phase is supportive. With
modern methods of management of fluid and electrolyte disorders
and of hypertension, no patient should die of the complications of
ARF. Of the 95% who survive, approximately one-third are at risk
of having chronic sequelae. The chronic course is characterized
predominantly by the hemodynamic sequelae of the renal lesion
produced during the acute stage. Motor, sensory, or intellectual
deficits; diabetes; myocardial infarctions; or intestinal strictures
are infrequent. We believe that enough evidence supports the
hypothesis that the progressive renal failure of HUS is due to the
glomerular and tubulo-interstitial scarring related to the initial
decrease of the nephron mass by the acute microangiopathic
process, and not to persistence or recurrence of the original
disease.
Three courses of progression to ESRF have been described.
Children with the most severe forms do not recover from the ARF
and enter directly into a dialysis and transplantation program. A
second group recovers renal function partially but with persistent
proteinuria and hypertension; subsequent progression to ESRF
occurs in two to five years. The third group, the majority of those
who progress to renal failure, ultimately initially recover normal
serum creatinine and creatininc clearance levels; some of these
patients do, however, develop proteinuria and/or hypertension.
These children progress to ESRF after more than five years, at
times as late as 20 years after the acute disease. Treatment in the
later years seeks to prevent the progression of chronic renal
insufficiency. Transplantation is indicated in this form of HUS, as
there is little, if any, risk of recurrence, and the prognosis is similar
to that of patients who receive renal transplants for other diseases.
DR. JOHN T. HARRINUTON (Dean, Tufts University School of
Medicine, Boston, Massachusetts, USA): Dr. Repetto, you said that
few patients over the age of three develop "classic" HUS. What
accounts for this immunity in children older than three? Do we
know what specific antibodies are responsible?
DR. REPETITO: This is a very interesting question. I know of no
data based on specific studies to answer it, but one can speculate.
In Argentina, these children appear to be in contact with the
verotoxin in the second half of the first year of age, when most of
them stop being breast-fed and start incorporating meat and
unpasteurized milk into their diet. Due the high prevalence of
VTEC in our country, susceptible children would develop HUS
then. There seems to be some kind of immunity either to the
VTEC or to the toxin; there have been no reports of well-
documented recurrences in this type of HUS, although no specific
immunity has been found. Children over three years could have
the same kind of protection if they are among those who had
VTEC infection without developing HUS. In the group studied by
Lopez et al, 19% of children with diarrhea not developing 1-TUS
had either VTEC in the stools, production of verotoxin from the
stool culture, or serum antibodies against verotoxin [29, 30]. The
possibility also exists that verotoxin receptors are differently
expressed at different ages. We have seen patients who developed
HUS shortly after their arrival from other countries. Some of their
older siblings presented bloody diarrhea, but we could not find
any laboratory evidence of even subclinical HUS.
DR. MANUEL MARTINEZ-MALDONADO (Professor and Vice-chair,
Department of Medicine, Emory University School of Medicine,
Atlanta, Georgia, USA): Have any attempts been made to biopsy
the kidneys of the patients in whom proteinuria, hypertension, or
both occur one year or more after acute HUS? If so, what lesion
is found? Thrombotic microangiopathy is mostly part of the acute
response. If later lesions are also thrombotic microangiopathy, are
47.1
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these re-exposure to toxin from shiga-like E. coli 0157:H7 or
"memory of cells" to other stimuli?
DR. REPETTO: Habib et a! reported the histologic findings in
sequential biopsies obtained during the acute period and one year
later [4]. When they correlated the clinical data with the late
biopsy results, they found that the patients who had hypertension,
proteinuria, and/or any decrease of creatinine clearance showed
the typical findings associated with the chronic renal sequelae,
namely, expansion of the mesangium, increased mesangial cellu-
larity, interstitial infiltrates, tubular atrophy, and focal glomerular
sclerosis. This has also been the experience of Gallo and his team
[3, 64].
DR. MARTINEZ-MALDONADO: Was thrombotic microangiopathy
present in the followup?
DR. REPETFO: No. Dr. Habib was very careful in looking for that
feature, and she could not find any sign of acute thrombotic
microangiopathy.
DR. MARTINEZ-MALDONADO: Let me return to Dr. Harrington's
question. In Argentina, if lesions of thrombotic microangiopathy
presented later, it could mean one of two things: either a
re-exposure to the verotoxin or "memory" of the kidney in its
reponse to other stimuli, but the response is the same. I wonder
what you think about that.
DR. REPETFO: We have never seen recurrences of HUS in
children who present with the typical epidemic form. Nor have I
recalled this fact in my talks with other pediatric nephrologists in
Argentina. The lack of recurrences probably is due to some kind
of immunity against the VTEC prevalent in our country or to the
toxin, but I don't think that this has anything to do with the kidney
itself. We usually tell the parents of these children, if we are sure
that we are dealing with the epidemic diarrheal form, that with
our experience gathered over four decades, the disease is highly
unlikely to recur. Patients who do develop recurrences clearly
have atypical forms of HUS, and most of them have more than
one recurrence, at times associated with hypocomplementemia
[551.
DR. NIcoLAos E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston): First, I would like to make a
comment. Regarding the increased susceptibility of young chil-
dren to epidemic HUS, the shiga-toxin receptor is now well
characterized. It would be of interest to look for different
expression of the receptor in young children versus older age
groups. It is possible that this could differ as a function of age.
My question relates to your comment that only supportive care
is indicated in patients with epidemic HUS. Although so-called
atypical HUS clearly has a worse outcome, epidemic HUS does
not strike me as a benign disorder, given that as many as 5% of the
affected children die in the acute phase, about 5% develop CNS
sequelae, some children never recover from ARF, and about 40%
develop long-term renal abnormalities. How vigorously have
therapies such as plasma infusion or exchange been studied in this
disorder? One might make the case for using these approaches in
the children who present with the most serious clinical character-
istics.
DR. REPETrO: Regarding your comment, I believe that the
studies of receptors comprise a new avenue for research that
could yield important knowledge for the management of HUS.
Now, let me answer your question. Numerous studies have
reported results of treatment in the acute phase [16—21], testing
inhibitors of platelet aggregation, anticoagulants, or high-dose
intravenous gamma globulin. Unfortunately, results generally
have been discouraging. Three carefully designed studies in
populations in which most children had the diarrhea! form were
prospective and controlled. One was performed by Drs. Vitacco
and coworkers in Buenos Aires many years ago [171. At that time,
because intravascular coagulation was believed to be responsible
for HUS, some groups advocated the use of heparin. These
authors studied children with the most severe forms of epidemic
HUS, comparing heparin versus conventional treatment in a
randomly selected control group. Not only they did not find any
benefit of heparin treatment, but they noticed an increased risk of
intracranial hemorrhage. Two other more recent, multicentric,
prospective, and controlled studies came from Italy and France
[20, 95]. Because plasma infusion or plasmapheresis had been
reported as effective in the control of the acute phase of the
atypical forms of HUS—possibly because of the altered metabo-
lism of the vascular endothelial products that prevent the micro-
thrombosis—these investigators studied a total of 56 children,
about 80% of whom had associated gastroenteritis. Patients
treated with plasma infusion for two to three weeks had no better
outcome than did those control patients treated supportively, both
in the acute phase and during a mean followup of 16 and 12
months. My own belief is that epidemic HUS is a one-shot disease
and that by the time the patients get to us, the thrombotic
microangiopathy is already established. I believe that all efforts
should be directed towards preventing intestinal infection or the
effect of the verotoxin.
DR. Luis SALINAS-MADRIGAL (Professor of Pathology, Internal
Medicine and Pediatrics, St. Louis University Cell Sciences Center,
St. Louis, Missouri, USA): Horacio, I was very much interested in
the fact that cyclosporine does not influence the incidence of
recurrence of the disease in the epidemic form. We have trans-
planted kidneys into three adults with idiopathic HUS and one
patient with mitomycin-induced HUS. In those four patients,
cyclosporine seemingly produced early recurrence of the throm-
botic process in the graft. Does this mean that we are talking
about different entities when we discuss the idiopathic versus the
epidemic form? Might this explain many of the differences in the
response to treatment? You just mentioned plasma infusion as
being more effective in the idiopathic forms as compared with the
epidemic form; this is a fascinating difference, I think.
DR. REPETFO: We have transplanted kidneys into five children
with the atypical form of HUS. One had the recurrence that I
related in my discussion. The other four received triple therapy
with lower doses of cyclosporine, yet we have not seen either a
hematologic or a renal recurrence. The experience in other
centers in our country [87] and in France [86] with transplantation
in the epidemic enteropathic form is the same. Cyclosporine does
not seem to add to the risk of recurrence, But, as you just heard,
I still think that the analysis of its responsibility in recurrences is
quite difficult. We are aware of the effect of cyclosporine on the
endothelium and the mesangium, but its direct participation in
recurrences of HUS has yet to be proven. On the other hand, as
I said, I am convinced that we are talking of different pathogenetic
entities that produce the same clinical syndrome and pathologic
lesion. The nosologic problem is further increased by the fact that
evidence of verotoxin infection has been demonstrated in children
with HUS who did not present with diarrhea.
Nephrology Forum: HUS in children 1715
DR. ELVIRA ARRIZURIETA (Chief Laboratoiy of Experimental
Renal Medicine, Institute of Medical Research, University of Buenos
Aires School of Medicine, Buenos Aires): How can you make an
early diagnosis of CRF in a child who had HUS?
DR. REPETTO: Two methods can detect a minimal degree of
renal dysfunction, which is not the same as saying that the child
definitely will progress to renal failure. The first is determination
of the maximum filtration capacity, which requires, as I discussed,
a method for measuring GFR precisely. For routine clinical
purposes, the determination of microalbuminuria is simpler, but
we have to be careful in interpreting these very sensitive findings
and in presenting that information to the parents.
DR. ARRIZURIETA: Do you treat those children with low-protein
diets or medications to slow the progression of ESRD?
DR. REPETI'O: Yes, we start reducing the protein load and giving
them ACE inhibitors when proteinuria persists one year after the
acute event. We think that we might be able to prevent progres-
sion of ESRD, or at least slow it down, but we need more data to
confirm this conjecture.
DR. ARRIZURIETA: What is the VTEC type in this country?
DR. REI'E'vro: Lopez and coworkers showed that 0157:H7 E.
coli was only 2% of the verotoxin-producing E. coli isolated [29];
prevalence in other parts of the world ranges between 40% and
79%. There are sporadic reports of 011, 025:H2 etc. from our
country [96]. Both groups are conducting studies to gather more
information.
DR. JORGE FERRARIS (Chief of Pediatric Renal Transplantation,
Hospital Italiano, Buenos Aires): We think that the best predictor
of CRF is the length of the acute phase. For example, a patient
with a severe acute phase, more than 14 days of oligoanuria, has
a 90% chance of developing CRF; a patient with a moderate acute
phase, 7 to 14 days of oligoanuria, has a 30% chance; and a patient
with a mild acute phase, less than 7 days of oligoanuria, has less
than a 2% chance of developing CRF [97]. My question is, what
do you think about using leukocytosis in the acute phase as a
predictor of CRF [981?
DR. REPETrO: We have not looked at that specifically. British
groups have postulated that the leukocyte elastase is a putative
intermediate in triggering the lesion [99 —101], but I cannot answer
the question based on our own experience.
DR. FERRARIS: How long should the followup be in patients with
mild HUS?
DR. REPEvm: This question reveals part of a big dilemma in
following these children. The predictive correlations you men-
tioned are, of course, statistical, and we have had patients with
only I or 2 days of anuria who ended up in CRF. On the other
hand, we have seen infants with anuria lasting more than 10 days
who appear cured after more than three years of followup. We
have to establish more exact methods for predicting the final
outcome. This is why I follow these children until the end of their
growing period, that is, until they are about 20 years of age.
DR. RAMOM ExENI (Chief Department of Nephroloi, San Justo
Qzildren 's Hospital, Province of Buenos Aires): Do verotoxin
infections exist in the parents or siblings of affected patients?
DR. REPEITO: Studies have looked for familial contagion of the
VTEC [102]. In our country, a very recent publication reported
cumulative evidence of VTEC infection in more than 30% of
family members of children with diarrheal HUS [96].
DR. EXENI: A 1994 report suggested that an absorbent agent
might prevent HUS [1031. Is there any new medication that could
absorb the toxin?
DR. REPETFO: As you know, the Canadians are performing a
prospective study with an oral absorbent that seems to be capable
of absorbing the toxin. They reported preliminary results last year
at the International Pediatric Nephrology Meeting in Chile, and
we eagerly hope that they get good results. Also, I have been
talking with Dr. Monnens from Holland, who is working to
develop vaccines against the prevalent VTEC strains or the toxin
itself.
DR. ExENI: What is the incidence of hemolytic-uremic syn-
drome in Argentina as compared with other countries?
DR. REPETTO: Your own editorial estimates an incidence here
of 7 cases per 100,000 inhabitants against 2 per 100,000 in
countries with a supposedly high incidence [104]. At least 6000
pediatric cases have been registered in Argentina since 1964, so I
believe that 7 cases per 100,000 is obviously an underestimation.
DR. ExENI: Is there a relationship between the use of antibiotics
in the diarrheal stage and evolution of the disease?
DR. Rapnrro: This question raises an important problem for
the pediatrician. The dysenteric type of diarrhea in the prodromal
period mimics that of bacterial origin and prompts primary
physicians to give antibiotics. Pavia et al did report a higher risk of
HUS in children treated with antibacterial drugs [105]. On the
other hand, a randomized Canadian study showed that the use of
trimethoprim-sulfamethoxazole did not affect the incidence of
HUS [106]. The speculation is that more verotoxin could be
liberated by the massive destruction of germs. The inoculum
might be one of the determinants of the severity of the disease.
Robinson and coworkers demonstrated a clear dose-dependent
inhibition of mesangial cell mitogenesis by verotoxin [107].
DR. PABLO MASSARI (Chief Renal Service, Hospital-Privado-
Centro Medico de Córdoba, Córdoba, Argentina): We are always
arguing with our pediatricians about patients reaching ESRF 22 to
25 years after an acute HUS, after they have had a course without
symptoms and laboratory abnormalities. How can you be sure that
the cause of this late ESRF is the much earlier episode of HUS?
DR. REPETrO: I agree with you that one cannot be certain, but
at least we can rule out several other causes leading to CRF. Then
HUS becomes a plausible cause. In the early years of dealing with
these patients, we saw some children who developed nephrotic-
range proteinuria without renal insufficiency. Treating few of
these children with steroids (as if they had idiopathic nephrotic
syndrome) did not result in any change in protein excretion.
DR. HARRINGTON: Is there a good experimental model of HUS
in which we could investigate the role of intermediate metabolites
or factors like cytokines, ICAMs, and all the other fancy stuff?
DR. REPEno: No experimental model has been produced in the
laboratory, with the exception of a potential and not-well-defined
toxic model in monkeys, published in the veterinary literature
[108). Interestingly, a few days ago, at an international symposium
held in Buenos Aires, Dr. Mohamed Karmali reviewed data on a
spontaneous canine model of the disease. Alabama greyhounds
develop a diffuse microangiopathy both pathologically and histo-
logically similar to HUS. They start by having ulcers in the skin,
which is not seen in the human disease, and renal involvement
follows. The investigators are taking extreme care of the dogs,
treating them as if they were in a spa, trying to put them in the best
situation to study them experimentally [109].
1716 Nephrology Forum: HUS in children
DR. HARRINOTON: What is the specific pathophysiologic cause
of the CNS abnormalities in HUS? Is it simply hypertension, or is
there evidence of a cerebral microangiopathy as well?
DR. REPETFO: Most of the CNS symptoms are present early in
the acute period and tend to improve with adequate management
of the hypertension and the fluid and electrolyte derangements.
Yet some patients develop encephalic hemorrhages documented
by MR scan [110], and autopsy studies have shown microthrombi,
infarcts, and hemorrhage in a variety of CNS regions [33, 111—
113].
DR. MADIAS: Low birth weight has been associated with small
kidneys, decreased number of nephrons, and future development
of hypertension [114]. Also, there is experimental support for
intrauterine growth retardation resulting in hypertension and
renal disease in the rat [115]. Have any studies linked low birth
weight with progression to ESRF in HUS?
DR. REPETI'O: I am not aware of any study in that respect, but
our own patients with HUS generally are well nourished and have
very good physical development.
DR. MADIAs: Since you mentioned that your current policy is to
initiate treatment in children who exhibit persistent proteinuria
after one year from the acute episode of HUS, I would consider it
reasonable to initiate treatment at the microalbuminuric stage. In
view of the progressive nature of the renal disease and the safety
profile of available therapies, I would not hesitate to intervene at
the stage of microalbuminuria.
DR. REPETrO: I could agree with you, and we are thinking of
doing that. The problem is that no one has yet verified that the
remaining nephrons are hyperfunctioning in this clinical model. If
you are very critical, you might not decide to start treatment at
that early stage. I believe that a prospective research study should
be developed before implementing this approach as routine
treatment. Let me point out that the results showing the propor-
tion of patients arriving at ESRF came from a time when we did
not aggressively treat patients in the chronic stage. We still don't
know what is going to happen now that we are routinely using
ACE inhibitors and reducing the dietary protein load.
DR. RODOLFO S. MARTIN (Career Investigator, Institute of Med-
ical Research, University of Buenos Aires School of Medicine): Has
our new knowledge gained about shiga-like toxins (verocytotoxin)
prompted any dietary measures or vaccines for preventing the
syndrome?
DR. REPETFO: Yes, three areas promise hope for preventing
HUS. One is the public health area. Adequate counseling and
public awareness should reduce the risk of consuming under-
cooked meat [116], unpasteurized cheese [117], and raw milk
[118]. A group from La Plata, Province of Buenos Aires, reported
that a high proportion of their patients develop HUS as a result of
drinking milk obtained directly from cows [119]. I also believe that
reporting of cases occurring in nursing homes or day-care centers
should be mandatory [118].
A second approach is, as you mentioned, vaccines. I believe that
we do not have the necessary pharmacologic infrastructure to
develop them in our country. Fortunately, efforts in Canada and
in Holland are proceeding (personal communications).
The third approach, as I mentioned in my answer to Dr. Exeni,
is the use of orally administered toxin-binding resins, I should
mention that antimotility agents are contraindicated in children
with acute diarrhea. Two studies have shown an increased risk of
HUS and increased severity of neurologic manifestations with
their use [36, 120].
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NOTE ADDED IN PROOF
A significantly increased number of neutrophils within the glomeruli of
D+ HUS was reported in a recent multicentric pathology study in
England.
INWARD CD, HOWIE Al, FITZPATRICK MM, RAFAAT F, MILF0RD DV, AND
TAYLOR CM ON BEHALF OF THE BRITISH ASSOCIATION FOR PAEDIATRIC
NEPHROLOGY. Renal histopathology in fatal cases of diarrhoea-associated
haemolytic uraemic syndrome. Paediatr Nephrol 11:556—559, 1997
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